Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQTNASDAQ:BEAMNYSE:BHCNASDAQ:MGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$14.37+6.4%$14.02$6.99▼$17.75$1.71B1.762.27 million shs2.44 million shsBEAMBeam Therapeutics$18.58+9.3%$17.39$13.53▼$35.25$1.87B2.351.49 million shs3.90 million shsBHCBausch Health Companies$4.75+2.6%$4.85$3.96▼$9.85$1.74B0.342.55 million shs991,688 shsMGTXMeiraGTx$6.00+9.5%$5.67$3.85▼$8.75$482.19M1.3371,277 shs436,494 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+1.81%-1.17%-5.66%-8.22%+69.51%BEAMBeam Therapeutics-0.87%+4.17%+6.80%-40.31%-30.58%BHCBausch Health Companies-0.32%+0.59%-2.84%-35.18%-26.18%MGTXMeiraGTx+0.37%+2.24%-6.64%-14.11%+10.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.013 of 5 stars3.41.00.00.02.81.70.6BEAMBeam Therapeutics2.7844 of 5 stars4.51.00.00.01.32.50.6BHCBausch Health Companies4.6208 of 5 stars2.95.00.04.03.41.71.9MGTXMeiraGTx4.5862 of 5 stars3.52.00.04.82.72.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8030.83% UpsideBEAMBeam Therapeutics 3.00Buy$48.75162.38% UpsideBHCBausch Health Companies 1.86Reduce$7.4256.14% UpsideMGTXMeiraGTx 3.00Buy$24.00300.00% UpsideCurrent Analyst Ratings BreakdownLatest MGTX, BHC, BEAM, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/14/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.005/7/2025BEAMBeam TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $55.005/7/2025BEAMBeam TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.005/7/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.005/2/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/9/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/7/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/7/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.504/3/2025ARQTArcutis BiotherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$212.82M8.05N/AN/A$0.94 per share15.29BEAMBeam Therapeutics$63.58M29.39N/AN/A$12.04 per share1.54BHCBausch Health Companies$9.73B0.18$5.05 per share0.94($0.89) per share-5.34MGTXMeiraGTx$34.51M13.97N/AN/A$2.17 per share2.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%8/13/2025 (Estimated)BEAMBeam Therapeutics-$132.53M-$4.61N/AN/AN/A-41.07%-16.22%-10.94%8/5/2025 (Estimated)BHCBausch Health Companies-$46M-$0.11N/A1.020.37-0.48%-577.82%5.24%7/30/2025 (Estimated)MGTXMeiraGTx-$84.03M-$2.32N/A15.790.37-633.05%-146.38%-53.05%8/11/2025 (Estimated)Latest MGTX, BHC, BEAM, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGTXMeiraGTx-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million3/13/2025Q4 2024MGTXMeiraGTx-$0.48-$0.50-$0.02-$0.50$1.50 million$21.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABEAMBeam Therapeutics$0.904.84%N/AN/A N/ABHCBausch Health CompaniesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.672.462.38BEAMBeam TherapeuticsN/A5.695.69BHCBausch Health CompaniesN/A0.860.62MGTXMeiraGTx0.862.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ABEAMBeam Therapeutics99.68%BHCBausch Health Companies78.65%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%BEAMBeam Therapeutics3.50%BHCBausch Health Companies8.05%MGTXMeiraGTx7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million105.93 millionOptionableBEAMBeam Therapeutics510100.56 million79.33 millionOptionableBHCBausch Health Companies19,900365.57 million338.06 millionOptionableMGTXMeiraGTx30080.37 million71.59 millionOptionableMGTX, BHC, BEAM, and ARQT HeadlinesRecent News About These CompaniesShort Interest in MeiraGTx Holdings plc (NASDAQ:MGTX) Increases By 16.9%June 5 at 4:25 PM | marketbeat.comNuveen Asset Management LLC Boosts Stock Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)June 5 at 3:43 AM | marketbeat.comNorthern Trust Corp Boosts Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)May 28, 2025 | marketbeat.comWoodline Partners LP Invests $9.35 Million in MeiraGTx Holdings plc (NASDAQ:MGTX)May 25, 2025 | marketbeat.comMeiraGTx (NASDAQ:MGTX) Cut to Sell at Wall Street ZenMay 24, 2025 | marketbeat.comFY2025 EPS Estimates for MeiraGTx Cut by Chardan CapitalMay 21, 2025 | marketbeat.com12,197,737 Shares in MeiraGTx Holdings plc (NASDAQ:MGTX) Bought by SanofiMay 19, 2025 | marketbeat.comProsight Management LP Sells 509,733 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX)May 17, 2025 | marketbeat.comMeiraGTx (NASDAQ:MGTX) Given New $35.00 Price Target at Chardan CapitalMay 16, 2025 | marketbeat.comMeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual MeetingMay 13, 2025 | globenewswire.comMeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comMeiraGTx Reports First Quarter 2025 Financial and Operational ResultsMay 13, 2025 | globenewswire.comFDA grants RMAT status to MeiraGTx’s Parkinson’s treatmentMay 11, 2025 | investing.comMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s DiseaseMay 9, 2025 | finance.yahoo.comMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's DiseaseMay 9, 2025 | globenewswire.comMeiraGTx (NASDAQ:MGTX) Trading Down 8.7% - Here's What HappenedMay 7, 2025 | marketbeat.comCone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and moreApril 29, 2025 | globenewswire.comRichard Giroux Sells 24,000 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) StockApril 23, 2025 | insidertrades.comInsider Selling: MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Sells 47,500 Shares of StockApril 9, 2025 | insidertrades.comMeiraGTx Holdings: Gaining Regulatory FocusMarch 25, 2025 | seekingalpha.comMeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near FutureMarch 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGTX, BHC, BEAM, and ARQT Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$14.37 +0.86 (+6.37%) Closing price 04:00 PM EasternExtended Trading$14.34 -0.02 (-0.17%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Beam Therapeutics NASDAQ:BEAM$18.58 +1.58 (+9.29%) Closing price 04:00 PM EasternExtended Trading$18.66 +0.08 (+0.43%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Bausch Health Companies NYSE:BHC$4.75 +0.12 (+2.59%) Closing price 03:59 PM EasternExtended Trading$4.71 -0.04 (-0.84%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.MeiraGTx NASDAQ:MGTX$6.00 +0.52 (+9.49%) Closing price 04:00 PM EasternExtended Trading$6.00 0.00 (-0.08%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
